March 21, 2025

Preserflo MicroShunt Shows Positive Benefit-to-Risk Ratio in Patients With Normal Pressure Glaucoma

92.5% of eyes were medication-free at 12 months, compared with 0% preoperatively.

Conexiant

March 18, 2025

Parafoveal Area of the Retina: A Biomarker for Systemic Diseases

Retinal thinning was linked to MS, type 2 diabetes, hypertension, and hyperlipidemia, among others.

Conexiant

March 18, 2025

FDA Approves Expanded Label for ILUVIEN

The fluocinolone acetonide intravitreal implant is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, as well as DME.

Conexiant

March 14, 2025

Study Demonstrates Outcomes of CNV Removal for hESC-RPE

“Safe CNV removal is a prerequisite for successful hESC-RPE transplantation in patients with wet AMD,” researchers found.

Conexiant

March 14, 2025

Higher Alcohol Consumption Associated with Higher Odds of Glaucoma

Women who consumed four or more drinks per week had a 52% increased risk of POAG.

Conexiant

March 13, 2025

Study Assesses Eye Movement Impairment in Adults with Alcohol Use Disorder

Tolerance may explain why participants with AUD showed less impairment in smooth pursuit tasks, but not in saccadic movement.

Conexiant

March 13, 2025

Vision Improvements With Gene Therapy for Pediatric Retinal Dystrophy

After intervention, treated eyes showed improvements to a mean of 0.9 logMAR (range: 0.8–1.0), while untreated eyes became unmeasurable at final follow-up.

Conexiant

March 12, 2025

LiGHT Trial Data Shows Efficacy in Decreasing Medication Burden with SLT

60.5% of eyes required no further medical or surgical treatment after 3 years of eye drop use when patients switched to SLT.

Conexiant

March 12, 2025

Selenium Supplementation Shows Potential Temporary Improvement for Graves Ophthalmopathy

Benefits observed at 3 months waned by 6 months.

Conexiant